Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by WCM Investment Management LLC

WCM Investment Management LLC grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 33.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,367 shares of the medical research company’s stock after purchasing an additional 2,589 shares during the quarter. WCM Investment Management LLC’s holdings in Charles River Laboratories International were worth $2,056,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 1.1% in the first quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock valued at $1,638,290,000 after acquiring an additional 66,161 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 1.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after buying an additional 31,359 shares during the period. Allspring Global Investments Holdings LLC increased its position in Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after acquiring an additional 509,163 shares during the period. Clearbridge Investments LLC raised its stake in Charles River Laboratories International by 3.1% during the 1st quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock valued at $409,985,000 after acquiring an additional 45,079 shares during the last quarter. Finally, Meritage Group LP lifted its position in Charles River Laboratories International by 2.3% during the 1st quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock worth $320,336,000 after acquiring an additional 26,892 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRL has been the topic of a number of analyst reports. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Baird R W downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Barclays lowered their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. cut Charles River Laboratories International from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $217.54.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $220.69 on Tuesday. The business’s 50-day moving average price is $194.37 and its 200 day moving average price is $208.00. The company has a current ratio of 1.48, a quick ratio of 1.21 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $168.24 and a twelve month high of $275.00. The company has a market capitalization of $11.29 billion, a PE ratio of 27.62, a price-to-earnings-growth ratio of 5.80 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period last year, the company earned $2.72 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis. On average, research analysts predict that Charles River Laboratories International, Inc. will post 10.2 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback program on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).